Medincell secures €28 million in loans, extends debt maturity to July 2031

The financing includes early repayment of €20 million of EIB debt and is intended to better match maturities with expected cash flows from UZEDY and Olanzapine LAI.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.